Concepedia

Anna Polli

AP

Statistics

Publications

45

Citations

9.2K

H-Index

29

Active since

1992

Affiliations

Pfizer (United States)(Current)

Pfizer (Italy)

Peter MacCallum Cancer Centre

Massachusetts General Hospital

Seoul National University Hospital

Anna Polli is an author at Pfizer (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1992–2024

45

Publications

45

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

, , +15

First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Todd M. Bauer, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.1K citations · Full text

, , +16

A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea

Jonathan Webster, G. Piscitelli, Anna Polli et al. · New England Journal of Medicine · 1994 · 700 citations · Full text

, , +7

Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Daniel B. Costa, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2015 · 605 citations · Full text

, , +14

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Manfred Kaufmann, Emilio Bajetta, Luc Dirix et al. · Journal of Clinical Oncology · 2000 · 525 citations

, , +14

1–5 of 45